Cannabis Law Report

NOVEMBER 12, 2021

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, 0.59, 95% CI [0.36–0.97]),

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. These statements relate to future events or future performance. from 2020 to 2030 and generate revenue of $151.7 billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JANUARY 27, 2022

The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

Clinical Trials 52

Clinical Trials Therapy Cannabinoids Topical 52

Cannabis Law Report

JULY 8, 2021

About Enveric Biosciences Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. These statements relate to future events or future performance. ” This product is not approved for marketing anywhere in the world.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Del Morgan & Co.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS). Additional information on cannabis and PTSD is available from NORML.

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

NOVEMBER 12, 2021

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

OCTOBER 5, 2021

Investors can register for the event here and view the live presentation here. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. a necessary question to address as medical marijuana becomes more accessible.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Otherside Farms

JULY 8, 2020

With over 100 potent cannabinoids that constitute the Cannabis plant, the possibilities of health benefits are ample. The healthcare industry is seeing significant investments in clinical trials to prove the health benefits of cannabis. The presence of cannabinoids can reduce muscle ache and ease inflammation.

Marijuana 105

Marijuana Sleep Clinical Trials Events 105

CannaMD

MAY 25, 2021

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. THC, CBD & THE ECS. In their summary, the study’s authors noted that.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Cannabis Law Report

JANUARY 4, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

MMJ Recs

JULY 11, 2024

It is often caused by life events such as stress, anxiety, or a significant change in routine. Medical marijuana refers to the use of cannabis and cannabinoids for medical purposes, such as using cannabis for insomnia relief, to alleviate symptoms, or to treat conditions under medical supervision.

Sleep 111

Sleep Treatment Research and Development Therapy 111

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. 13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e.,

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In this position, Mr. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 1, 2021

The Company filed patent applications protecting its discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. About Can-Fite BioPharma Ltd. Can-Fite BioPharma.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

Otherside Farms

JANUARY 14, 2019

While there is a need for more clinical trials on the subject, users and alternative-therapy practitioners worldwide continue to buy cannabis seeds online for healing physical and mental ailments. Here are five popular medicinal uses of cannabis with low concentration of the intoxicating chemical compound tetrahydrocannabinol (THC).

Clinical Trials 49

Clinical Trials Strains Therapy Medicine 49

MMJ Recs

JULY 3, 2024

Life events such as trauma, loss, or significant changes in personal circumstances can also trigger acute episodes of anxiety while social factors including interpersonal relationships, social expectations, and societal pressures further contribute to stress levels, influencing emotional resilience and coping mechanisms.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

OCTOBER 19, 2021

Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 1, 2021

Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 98

CBD THC Conditions Medicine 98

Green Relief

MAY 13, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64